AKEBIA THERAPEUTICS INC (AKBA) Stock Price, Quote, News and Overview
NASDAQ:AKBA - Nasdaq - US00972D1054 - Common Stock - Currency: USD
AKBA Quote, Performance and Key Statistics
3.92
+0.09 (+2.35%)
The current stock price of AKBA is 3.92 USD. In the past month the price increased by 61.32%. In the past year, price increased by 266.35%.
AKBA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.45 | 334.73B | ||
| AMGN | AMGEN INC | 14.13 | 157.78B | ||
| GILD | GILEAD SCIENCES INC | 14.22 | 136.94B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 115.95B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.82 | 56.53B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 39.44B | ||
| ARGX | ARGENX SE - ADR | 100.08 | 35.14B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.74 | 28.50B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.70B | ||
| NTRA | NATERA INC | N/A | 22.56B | ||
| BIIB | BIOGEN INC | 8.56 | 19.85B | ||
| INSM | INSMED INC | N/A | 16.56B |
Related stock screener links
About AKBA
Company Profile
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 181 full-time employees. The company went IPO on 2014-03-20. The firm is focused on developing and commercializing therapeutics. Its two preclinical development candidates are AKB-9090 and AKB-10108. The Company’s portfolio and hypoxia-inducible factor (HIF)-based commercialized products include Auryxia (ferric citrate) and Vafseo. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo, an oral HIF prolyl hydroxylase (HIF-PH), inhibitor. The company utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.
Company Info
AKEBIA THERAPEUTICS INC
245 First Street
Cambridge MASSACHUSETTS 02142 US
CEO: John P. Butler
Employees: 181
Phone: 16178712098
AKEBIA THERAPEUTICS INC / AKBA FAQ
What is the stock price of AKEBIA THERAPEUTICS INC today?
The current stock price of AKBA is 3.92 USD. The price increased by 2.35% in the last trading session.
What is the ticker symbol for AKEBIA THERAPEUTICS INC stock?
The exchange symbol of AKEBIA THERAPEUTICS INC is AKBA and it is listed on the Nasdaq exchange.
On which exchange is AKBA stock listed?
AKBA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AKEBIA THERAPEUTICS INC stock?
11 analysts have analysed AKBA and the average price target is 7.45 USD. This implies a price increase of 89.95% is expected in the next year compared to the current price of 3.92. Check the AKEBIA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AKEBIA THERAPEUTICS INC worth?
AKEBIA THERAPEUTICS INC (AKBA) has a market capitalization of 1.03B USD. This makes AKBA a Small Cap stock.
How many employees does AKEBIA THERAPEUTICS INC have?
AKEBIA THERAPEUTICS INC (AKBA) currently has 181 employees.
Is AKEBIA THERAPEUTICS INC (AKBA) expected to grow?
The Revenue of AKEBIA THERAPEUTICS INC (AKBA) is expected to grow by 28.22% in the next year. Check the estimates tab for more information on the AKBA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy AKEBIA THERAPEUTICS INC (AKBA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AKBA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AKBA, evaluating the profitability, health, valuation and growth aspects
- AKEBIA THERAPEUTICS INC (AKBA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AKEBIA THERAPEUTICS INC (AKBA) Sales and EPS estimates to see what analysts future expectations are.
- AKEBIA THERAPEUTICS INC (AKBA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AKEBIA THERAPEUTICS INC (AKBA) Insider and Institutional Ownership to learn about the owners and their transactions.
- AKEBIA THERAPEUTICS INC (AKBA) Stock Chart to make your own analysis
- AKEBIA THERAPEUTICS INC (AKBA) Latest news and press-releases to stay up to date.
Does AKEBIA THERAPEUTICS INC (AKBA) stock pay dividends?
AKBA does not pay a dividend.
When does AKEBIA THERAPEUTICS INC (AKBA) report earnings?
AKEBIA THERAPEUTICS INC (AKBA) will report earnings on 2025-08-06, before the market open.
What is the Price/Earnings (PE) ratio of AKEBIA THERAPEUTICS INC (AKBA)?
AKEBIA THERAPEUTICS INC (AKBA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.21).
What is the Short Interest ratio of AKEBIA THERAPEUTICS INC (AKBA) stock?
The outstanding short interest for AKEBIA THERAPEUTICS INC (AKBA) is 8.04% of its float. Check the ownership tab for more information on the AKBA short interest.
AKBA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to AKBA. When comparing the yearly performance of all stocks, AKBA is one of the better performing stocks in the market, outperforming 98.84% of all stocks.
AKBA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AKBA. AKBA may be in some trouble as it scores bad on both profitability and health.
AKBA Financial Highlights
Over the last trailing twelve months AKBA reported a non-GAAP Earnings per Share(EPS) of -0.21. The EPS increased by 8.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.61% | ||
| ROE | -184.34% | ||
| Debt/Equity | 1.89 |
AKBA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to AKBA. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 48.07% and a revenue growth 28.22% for AKBA